Modernizing the Development of Cancer Therapeutics.
Built on an efficacy-first model, Spanios is harnessing the powerful capabilities of Patient Derived Tumoroids (PDTs) to accelerate next-gen drug development.
We are transforming oncology research, therapeutic validation, and precision medicine.
By building the most physiologically relevant PDTs, innovators creating the next generation of cancer therapeutics can take the guesswork out of drug validation and accelerate their development timeline.
COMPASS & PDTs: Cancer Organoids with intact source TME
Our COMPASS platforms are uniquely empowered by our stable tumor models that are biobanked for rapid deployment & enabling reproducible studies
We maintain an intact & functional tumor microenvrionment (TME) for those whose studies require robust preclinical research models. Our unique 3D tumor models enable the recapitulation of patient-specific tumor-immune interactions to fast-track the search for novel cures and bring hope to millions of patients.
Our Technology: COMPASS model platform
Custom Organoid Modelling Platform for Accurate and Speedy Solutions
COMPASS 1
Proprietary platform containing epithelium and stroma. TME rich tumoroid.
COMPASS 2
Proprietary platform with epithelium and stroma co-cultured with PBMCs. Allogenic and activated PBMCs.
COMPASS 3
Dynamic liquid-liquid interface platform with epithelium and stroma co-cultured with PBMCs and utilizing physiological flow for oxygen delivery.
